Related Experiment Video
Updated: Oct 11, 2025
Bioluminescence Imaging of NADPH Oxidase Activity in Different Animal Models
Published on: October 22, 2012
Novel organoselenides (NSAIDs-Se derivatives) protect against LPS-induced inflammation in microglia by targeting the
Abstract:
Neuro-inflammation is an immune response of the central nervous system (CNS) to pathogens, and it is associated with a variety of neurodegenerative diseases. Microglial cells are the main category of macrophages in the CNS parenchyma, and they represent one of the most important cellular drivers and regulators of neuroinflammation. In this study, nine new organoselenium compounds based on the hybridization of nonsteroidal anti-inflammatory drugs (NSAIDs) skeleton and organoselenium motif (-SeCN and -SeCF3) were synthesized and their potential anti-neuroinflammatory effects were evaluated using LPS-induced BV2 mouse microglia. The cells were first treated with the organoselenium compounds and the extent of oxidative stress and inflammatory response of the cells was determined by measuring the levels of NO, ROS, IL-1β, and IL-18. Among the nine compounds, 1-39 and 1A-38 exhibited the most significant effect on oxidative stress and inflammatory response. Subsequent studies carried out with 1-39 and 1A-38 showed that both compounds could reduce the production of ROS in the cells, probably through down-regulating NOX2 and its downstream targets, including TXNIP (thioredoxin-interacting protein) and NLRP3 (NOD-like receptor protein 3). In addition, 1-39 and 1A-38 also suppressed the ability of the cells to secret IL-18 and IL-1β, which greatly dampened the response of the cells to LPS-induced inflammation. Our finding demonstrated that organoselenium compounds derived from NSAID might play an important role in the protection of brain microglia against inflammation-related neurodegenerative disease by potentially down-regulating the NOX2/NLRP3 signaling axis.
Insights
New organoselenium compounds derived from NSAIDs show potential in combating neuroinflammation. These compounds effectively reduced oxidative stress and inflammatory markers in microglia, suggesting a protective role against neurodegenerative diseases.
Area of Science:
- Neuroscience
- Immunology
- Medicinal Chemistry
Background:
- Neuroinflammation, an immune response in the central nervous system (CNS), is implicated in neurodegenerative diseases.
- Microglial cells are key regulators of neuroinflammation within the CNS parenchyma.
Purpose of the Study:
- To synthesize novel organoselenium compounds by hybridizing NSAID scaffolds with organoselenium moieties.
- To evaluate the anti-neuroinflammatory potential of these new compounds in an in vitro model of neuroinflammation.
Main Methods:
- Synthesis of nine organoselenium compounds incorporating -SeCN and -SeCF3 motifs.
- Assessment of anti-neuroinflammatory effects using lipopolysaccharide (LPS)-induced BV2 mouse microglia.
- Measurement of nitric oxide (NO), reactive oxygen species (ROS), IL-1β, and IL-18 levels to determine cellular oxidative stress and inflammatory responses.
Main Results:
- Compounds 1-39 and 1A-38 demonstrated significant reduction in oxidative stress and inflammatory markers.
- These compounds decreased ROS production, likely by down-regulating NOX2, TXNIP, and NLRP3 signaling.
- Compounds 1-39 and 1A-38 suppressed IL-18 and IL-1β secretion, mitigating LPS-induced inflammation.
Conclusions:
- Organoselenium compounds derived from NSAIDs show promise as therapeutic agents against neuroinflammation.
- These compounds may protect brain microglia by down-regulating the NOX2/NLRP3 signaling axis.
- Further investigation into these compounds could lead to novel treatments for inflammation-related neurodegenerative diseases.
